Search Results

Low Recruitment in a Double-Blind, Placebo-Controlled Trial of Ocrelizumab for Autoimmune Encephalitis: A Case Series and Review of Lessons Learned.

• Authors : Blackburn, Kyle M.; Denney, David A.; Hopkins, Steven C.

• Source: Neurology and Therapy. June, 2022, Vol. 11 Issue 2, p893, 11 p.

Record details

The Ultimate Targeted Therapy.

• Source: Forbes. 2007, Vol. 179, Issue 11, pages. 60

Record details

How Precious Metals Work Their Magic.

• Authors : Gross, Neil

• Source: Business Week. 2006, Issue 3975, pages. 75

Record details

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.

• Authors : Vande Walle, Lieselotte; Stowe, Irma B.; Sácha, Pavel

• Source: PLoS Biology. September 16, 2019, Vol. 17 Issue 9, e3000354.

Record details

Autoimmune disorders. (Drugwatch: a heads-up on pharmaceuticals in late-stage development).

• Source: Formulary. 2002, Vol. 37, Issue 10, pages. 546

Record details

Argos preclinical data.

• Source: R & D Focus Drug News. 2013.

Record details

American Inventors Develop Antagonist OX40 Antibodies and their Use in the Treatment of Inflammatory and Autoimmune Diseases.

• Source: Indian Patent News. 2010.

Record details

DART Program MacroGenics partnering opportunity, Worldwide.

• Authors : Fanger, Gary R.

• Source: R & D Focus Drug News. 2007.

Record details

sc 28AT TcLand provides development update.

• Source: R & D Focus Drug News. 2006.

Record details

NIP 45 based therapy Boston Life Sciences discontinued.

• Source: R & D Focus Drug News. 2006.

Record details